Lupin latest target of Teijin/Takeda's febuxostat defense
This article was originally published in Scrip
India's Lupin has become the latest target to move into the legal sights of two Japanese firms over its plans to launch a generic version of the gout drug Uloric (febuxostat) in the US.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.